What is a primary function of Prolia (Denosumab)?

Prolia, which is the brand name for Denosumab, is primarily indicated for the treatment of osteoporosis in postmenopausal women and for patients with other conditions that involve bone loss. Its mechanism of action involves inhibiting the activity of osteoclasts, the cells responsible for bone resorption, thereby leading to an increase in bone mineral density. This is particularly important for individuals at risk of fractures due to weakened bones. By increasing the density of bones, Prolia helps reduce the risk of osteoporosis-related fractures, making it a critical treatment option in this patient population.

The other choices pertain to different medical conditions and treatments that do not relate to the effects of Denosumab. Reducing high blood pressure, enhancing metabolic rate, and alleviating respiratory issues are not functions associated with Prolia, which is specifically focused on bone health management.